Determinants of steady-state torasemide pharmacokinetics: Impact of pharmacogenetic factors, gender and angiotensin II receptor blockers

Clinical Pharmacokinetics

Volumn 47, Issue 5, 2008, Pages 323-332

  Werner, Dierk ^a   Werner, Ulrike ^b   Meybaum, Annett ^a   Schmidt, Boris ^c   Umbreen, Sumaira ^c   Grosch, Anton ^a   Lestin, Heiko G ^a   Graf, Bernhard ^a   Zolk, Oliver ^b   Fromm, Martin F ^b  

^a HELIOS KLINIKEN SCHWERIN   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c Technical University   (Germany)

Author keywords

Antihypertensives, pharmacokinetics; Gender differences; Loop diuretics, pharmacokinetics; Pharmacogenetics; Pharmacokinetic modelling; Torasemide, pharmacokinetics

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; CYTOCHROME P450 2C9; IRBESARTAN; LOSARTAN; ORGANIC ANION TRANSPORTER 2; TORASEMIDE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INDICATION; FEMALE; GENDER; GENETIC POLYMORPHISM; GENOTYPE; HEART FAILURE; HUMAN; HYPERTENSION; MALE; OPEN STUDY; PHARMACOGENETICS; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STEADY STATE;

AGED; ANALYSIS OF VARIANCE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; GENOTYPE; HALF-LIFE; HUMANS; MALE; ORGANIC ANION TRANSPORTERS; PHARMACOGENETICS; SEX CHARACTERISTICS; SULFONAMIDES;

EID: 41949120397     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200847050-00003     Document Type: Article

References (39)

1. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112: e154-235
2. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26: 1115-40
3. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-53
4. Uchida T, Yamanaga K, Nishikawa M, et al. Anti-aldosteronergic effect of torasemide. Eur J Pharmacol 1991; 205: 145-50
5. Knauf H, Mutschler E. Clinical pharmacokinetics and pharmacodynamics of torasemide. Clin Pharmacokinet 1998; 34: 1-24
6. Vormfelde SV, Schirmer M, Hagos Y, et al. Torsemide renal clearance and genetic variation in luminal and basolateral organic anion transporters. Br J Clin Pharmacol 2006; 62: 323-35
7. Hagos Y, Bahn A, Vormfelde SV, et al. Torasemide transport by organic anion transporters contributes to hyperuricemia. J Am Soc Nephrol 2007; 18: 3101-9
8. König J, Seithel A, Gradhand U, et al. Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch Pharmacol 2006; 372: 432-43
9. König J, Cui Y, Nies AT, et al. Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J Biol Chem 2000; 275: 23161-8
10. König J, Cui Y, Nies AT, et al. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol 2000; 278: G156-64
11. Hsiang B, Zhu Y, Wang Z, et al. A novel human hepatic organic anion transporting polypeptide (OATP2): identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 1999; 74: 37161-8
12. Tirona RG, Leake BF, Merino G, et al. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem 2001; 276: 35669-75
13. Niemi M, Kivisto KT, Hofmann U, et al. Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). Br J Clin Pharmacol 2005; 59: 602-4
14. Niemi M, Schaeffeler E, Lang T, et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 2004; 14: 429-40
15. Miners JO, Rees DL, Valente L, et al. Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torsemide metabolism. J Pharmacol Exp Ther 1995; 272: 1076-81
16. Miners JO, Coulter S, Birkett DJ, et al. Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes. Pharmacogenetics 2000; 10: 267-70
17. Lee CR, Goldstein JA, Pieper JA. Cytochrome P 450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002; 12: 251-63
18. Vormfelde SV, Engelhardt S, Zirk A. CYP2C9 polymorphisms and the inter-individual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide. Clin Pharmacol Ther 2004; 76: 557-66
19. Vormfelde SV, Schirmer M, Toliat, et al. Genetic variation at the CYP2C locus and its association with torsemide biotransformation. Pharmacogenomics J 2006; 7: 200-11
20. Yasar U, Tybring G, Hidestrand M, et al. Role of CYP2C9 polymorphism in losartan oxidation. Drug Metab Dispos 2001; 29: 1051-6
21. Taavitsainen P, Kiukaanniemi K, Pelkonen O. In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists. Eur J Clin Pharmacol 2000; 56: 135-40
22. Fischer TL, Pieper JA, Graff DW, et al. Evaluation of potential losartan-pheny-toin drug interactions in healthy volunteers. Clin Pharmacol Ther 2002; 72: 238-46
23. Ishiguro N, Maeda K, Kishimoto W, et al. Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. Drug Metab Dispos 2006; 34: 1109-15
24. Yamashiro W, Maeda K, Hirouchi M, et al. Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab Dispos 2006; 34: 1247-54
25. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lower-ing drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006; 80: 565-81
26. Kassler-Taub K, Littlejohn T, Elliott W, et al. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators. Am J Hypertens 1998; 11: 445-53
27. Schupp M, Lee LD, Frost N, et al. Regulation of peroxisome proliferator-activated receptor gamma activity by losartan metabolites. Hypertension 2006; 47: 586-9
28. Polinko M, Riffel K, Song H, et al. Simultaneous determination of losartan and EXP3174 in human plasma and urine utilizing liquid chromatography/tandem mass spectrometry. J Pharm Biomed Anal 2003; 33: 73-84
29. Grothusen C, Umbreen S, Konrad I, et al. EXP3179 inhibits collagen-dependent platelet activation via glycoprotein receptor-VI independent of AT1-receptor antagonism: potential impact on atherothrombosis. Arterioscler Thromb Vasc Biol 2007; 27: 1184-90
30. US FDA Center for Drug Evaluation and Research (CDER). Guidance for industry: bioanalytical method validation [online]. Rockville (MD): CDER, 2001 May. Available from URL: http://www.fda.gov/cder/guidance/4252fnl.htm [Accessed 2008 Mar 26]
31. Werner U, Werner D, Pahl A, et al. Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry. Biomed Chromatogr 2002; 16: 56-60
32. Egger T, Dormann H, Ahne G, et al. Cytochrome P450 polymorphisms in geriatric patients: impact on adverse drug reactions - a pilot study. Drugs Aging 2005; 22: 265-72
33. Vormfelde SV, Toliat MR, Schirmer M, et al. The polymorphisms Asn120Asp and Val174Ala in OATP1B1 and the CAP2C9 allele*3 independently affect torsemide pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. Epub 2007 Nov 28
34. Buist SC, Klaassen CD. Rat and mouse differences in gender-predominant expression of organic anion transporter (Oat1-3; Slc22a6-8) mRNA levels. Drug Metab Dispos 2004; 32: 620-5
35. Cerrutti JA, Quaglia NB, Brandoni A, et al. Effects of gender on the pharmacokinetics of drugs secreted by the renal organic anions transport systems in the rat. Pharmacol Res 2002; 45: 107-12
36. Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet 2003; 42: 107-21
37. Tanaka E. Gender-related differences in pharmacokinetics and their clinical significance. J Clin Pharm Ther 1999; 24: 339-46
38. Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther 2008; 83: 460-70
39. Brunner HR. The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations. Am J Hypertens 1997; 10: 311S-317S